Peter Clark to Disease Progression
This is a "connection" page, showing publications Peter Clark has written about Disease Progression.
Connection Strength
0.758
-
Polosukhina D, Love HD, Correa H, Su Z, Dahlman KB, Pao W, Moses HL, Arteaga CL, Lovvorn HN, Zent R, Clark PE. Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. Mol Oncol. 2017 04; 11(4):405-421.
Score: 0.122
-
Stabler S, Koyama T, Zhao Z, Martinez-Ferrer M, Allen RH, Luka Z, Loukachevitch LV, Clark PE, Wagner C, Bhowmick NA. Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One. 2011; 6(8):e22486.
Score: 0.083
-
Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2009 Jun; 9(6):821-30.
Score: 0.071
-
Bischoff CJ, Clark PE. Bladder cancer. Curr Opin Oncol. 2009 May; 21(3):272-7.
Score: 0.071
-
Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol. 2008 May; 20(3):307-14.
Score: 0.066
-
Clark PE, Stein JP, Groshen SG, Miranda G, Cai J, Lieskovsky G, Skinner DG. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol. 2004 Oct; 172(4 Pt 1):1342-7.
Score: 0.051
-
Clark PE, Hall MC, Miller A, Ridenhour KP, Stindt D, Lovato JF, Patton SE, Brinkley W, Das S, Torti FM. Phase II trial of combination interferon-alpha and thalidomide as first-line therapy in metastatic renal cell carcinoma. Urology. 2004 Jun; 63(6):1061-5.
Score: 0.050
-
Clark PE, Torti FM. Prostate cancer and bone metastases: medical treatment. Clin Orthop Relat Res. 2003 Oct; (415 Suppl):S148-57.
Score: 0.048
-
David SN, Arnold Egloff SA, Goyal R, Clark PE, Phillips S, Gellert LL, Hameed O, Giannico GA. MAGI2 is an independent predictor of biochemical recurrence in prostate cancer. Prostate. 2018 06; 78(8):616-622.
Score: 0.033
-
Chang SS, Boorjian SA, Chou R, Clark PE, Daneshmand S, Konety BR, Pruthi R, Quale DZ, Ritch CR, Seigne JD, Skinner EC, Smith ND, McKiernan JM. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016 Oct; 196(4):1021-9.
Score: 0.029
-
Austin DC, Strand DW, Love HL, Franco OE, Jang A, Grabowska MM, Miller NL, Hameed O, Clark PE, Fowke JH, Matusik RJ, Jin RJ, Hayward SW. NF-?B and androgen receptor variant expression correlate with human BPH progression. Prostate. 2016 Apr; 76(5):491-511.
Score: 0.028
-
Jin R, Yi Y, Yull FE, Blackwell TS, Clark PE, Koyama T, Smith JA, Matusik RJ. NF-?B gene signature predicts prostate cancer progression. Cancer Res. 2014 May 15; 74(10):2763-72.
Score: 0.025
-
Clayton DB, Stephany HA, Ching CB, Rahman SA, Tanaka ST, Thomas JC, Pope JC, Adams MC, Brock JW, Clark PE, Hayward SW, Matusik RJ, Milne GL. F2-isoprostanes as a biomarker of oxidative stress in the mouse bladder. J Urol. 2014 May; 191(5 Suppl):1597-601.
Score: 0.025
-
Ritch CR, Clark PE, Morgan TM. Restaging transurethral resection for non-muscle invasive bladder cancer: who, why, when, and how? Urol Clin North Am. 2013 May; 40(2):295-304.
Score: 0.023
-
DeGraff DJ, Cates JM, Mauney JR, Clark PE, Matusik RJ, Adam RM. When urothelial differentiation pathways go wrong: implications for bladder cancer development and progression. Urol Oncol. 2013 Aug; 31(6):802-11.
Score: 0.021
-
Rackley JD, Clark PE, Hall MC. Complementary and alternative medicine for advanced prostate cancer. Urol Clin North Am. 2006 May; 33(2):237-46, viii.
Score: 0.014